NASDAQ:COGT - Cogent Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.50
  • Forecasted Upside: 93.16 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$9.06
▼ -0.05 (-0.55%)
1 month | 3 months | 12 months
Get New Cogent Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COGT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COGT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.50
▲ +93.16% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $17.50, with a high forecast of $24.00 and a low forecast of $4.00. The average price target represents a 93.16% upside from the last price of $9.06.

Buy

The current consensus among 5 contributing investment analysts is to buy stock in Cogent Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2021Lifesci CapitalReiterated RatingOutperformN/A
i
Rating by S. Slutsky at Lifesci Capital
12/23/2020Piper SandlerInitiated CoverageOverweight$22.00 ➝ $22.00N/A
i
12/16/2020SVB LeerinkInitiated CoverageOutperform$20.00N/A
i
Rating by C. Liu at SVB Leerink LLC
11/10/2020WedbushBoost Price TargetOutperform$6.00 ➝ $24.00N/A
i
10/14/2020LADENBURG THALM/SH SHInitiated CoverageBuy$4.00N/A
i
4/12/2018Barrington ResearchInitiated CoverageOutperform ➝ Outperform$4.00Low
i
2/27/2018Chardan CapitalSet Price TargetBuy$7.00High
i
Rating by James McIlree at Chardan Capital
2/26/2018Barrington ResearchReiterated RatingBuy$4.00Medium
i
11/9/2017Chardan CapitalReiterated RatingBuy ➝ Buy$12.50 ➝ $7.00N/A
i
8/8/2017Roth CapitalSet Price TargetBuy$8.00Medium
i
Rating by William Gibson at Roth Capital
6/29/2017Roth CapitalInitiated CoverageBuy$7.65Medium
i
Rating by W. Gibson at Roth Capital
3/13/2017Chardan CapitalReiterated RatingBuy$12.50Medium
i
11/4/2016Chardan CapitalReiterated RatingBuy$12.50N/A
i
10/21/2016Chardan CapitalReiterated RatingBuy$12.50N/A
i
10/14/2016Barrington ResearchReiterated RatingOutperform$7.00N/A
i
7/12/2016Barrington ResearchReiterated RatingOutperformN/A
i
Rating by J. Goss at Barrington Research
(Data available from 6/16/2016 forward)
Cogent Biosciences logo
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $9.06
$8.79
$9.59

50 Day Range

MA: $8.38
$7.82
$9.11

52 Week Range

Now: $9.06
$1.61
$14.88

Volume

806,934 shs

Average Volume

338,896 shs

Market Capitalization

$347.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Cogent Biosciences?

The following sell-side analysts have issued research reports on Cogent Biosciences in the last twelve months: LADENBURG THALM/SH SH, Lifesci Capital, Piper Sandler, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for COGT.

What is the current price target for Cogent Biosciences?

4 Wall Street analysts have set twelve-month price targets for Cogent Biosciences in the last year. Their average twelve-month price target is $17.50, suggesting a possible upside of 93.2%. Wedbush has the highest price target set, predicting COGT will reach $24.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $4.00 for Cogent Biosciences in the next year.
View the latest price targets for COGT.

What is the current consensus analyst rating for Cogent Biosciences?

Cogent Biosciences currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe COGT will outperform the market and that investors should add to their positions of Cogent Biosciences.
View the latest ratings for COGT.

What other companies compete with Cogent Biosciences?

How do I contact Cogent Biosciences' investor relations team?

Cogent Biosciences' physical mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The technology company's listed phone number is 561-757-4000 and its investor relations email address is [email protected] The official website for Cogent Biosciences is www.cogint.com.